HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: In 2006, the class I/II HDAC inhibitor vorinostat was approved to treat patients with advanced cutaneous T-cell lymphoma (CTCL), which was followed by the 2009 approval of romidepsin for the same indication [136,137].